| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study
|
Braat, Arthur J A T
|
|
|
21 |
4 |
p. 561-570
|
article
|
| 2 |
Breast conservation therapy versus mastectomy for breast cancer
|
Thompson, Alastair M
|
|
|
21 |
4 |
p. 493-494
|
article
|
| 3 |
Breast conservation therapy versus mastectomy for breast cancer
|
Royce, Trevor J
|
|
|
21 |
4 |
p. 492-493
|
article
|
| 4 |
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
|
Qin, Shukui
|
|
|
21 |
4 |
p. 571-580
|
article
|
| 5 |
Childhood cancer care: closing equity gaps on the ground
|
Booth, Christopher M
|
|
|
21 |
4 |
p. 485-487
|
article
|
| 6 |
Correction to Lancet Oncol 2020; 21: 341–42
|
|
|
|
21 |
4 |
p. e182
|
article
|
| 7 |
Correction to Lancet Oncol 2020; 21: 508–18
|
|
|
|
21 |
4 |
p. e182
|
article
|
| 8 |
COVID-19: global consequences for oncology
|
The Lancet Oncology,
|
|
|
21 |
4 |
p. 467
|
article
|
| 9 |
FOLFOXIRI reintroduction in metastatic colorectal cancer
|
Glynne-Jones, Rob
|
|
|
21 |
4 |
p. 468-469
|
article
|
| 10 |
Holmium-166 radioembolisation after peptide receptor radionuclide therapy: much needed data to help inform future research
|
Fidelman, Nicholas
|
|
|
21 |
4 |
p. 478-479
|
article
|
| 11 |
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
|
Nestle, Ursula
|
|
|
21 |
4 |
p. 581-592
|
article
|
| 12 |
Is HER2-positive metastatic breast cancer still an incurable disease?
|
Lambertini, Matteo
|
|
|
21 |
4 |
p. 471-472
|
article
|
| 13 |
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
|
Hong, David S
|
|
|
21 |
4 |
p. 531-540
|
article
|
| 14 |
Less is more in radiotherapy target volume planning: lessons from the PET-plan trial
|
Faivre-Finn, Corinne
|
|
|
21 |
4 |
p. 481-483
|
article
|
| 15 |
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial
|
Davis, Kara L
|
|
|
21 |
4 |
p. 541-550
|
article
|
| 16 |
Nivolumab in paediatric cancer: children are not little adults
|
Mora, Jaume
|
|
|
21 |
4 |
p. 474-476
|
article
|
| 17 |
NTRK gene fusions: a rough diamond ready to sparkle
|
Rolfo, Christian
|
|
|
21 |
4 |
p. 472-474
|
article
|
| 18 |
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|
Pishvaian, Michael J
|
|
|
21 |
4 |
p. 508-518
|
article
|
| 19 |
Patience and commitment needed to fight very rare tumours
|
Ferreri, Andrés J M
|
|
|
21 |
4 |
p. 483-484
|
article
|
| 20 |
Pembrolizumab for triple-negative breast cancer
|
Stirrups, Robert
|
|
|
21 |
4 |
p. e183
|
article
|
| 21 |
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
|
Swain, Sandra M
|
|
|
21 |
4 |
p. 519-530
|
article
|
| 22 |
Precision oncology for pancreatic cancer in real-world settings
|
Kleeff, Jörg
|
|
|
21 |
4 |
p. 469-471
|
article
|
| 23 |
Preoperative endocrine therapy for ductal carcinoma in situ
|
Gourd, Elizabeth
|
|
|
21 |
4 |
p. e184
|
article
|
| 24 |
Risk of COVID-19 for patients with cancer
|
Wang, Hanping
|
|
|
21 |
4 |
p. e181
|
article
|
| 25 |
Risk of COVID-19 for patients with cancer
|
Xia, Yang
|
|
|
21 |
4 |
p. e180
|
article
|
| 26 |
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial
|
Shimada, Kazuyuki
|
|
|
21 |
4 |
p. 593-602
|
article
|
| 27 |
Sustainable care for children with cancer: a Lancet Oncology Commission
|
Atun, Rifat
|
|
|
21 |
4 |
p. e185-e224
|
article
|
| 28 |
Sustainable care for indigenous children with cancer
|
Valery, Patricia C
|
|
|
21 |
4 |
p. 489-491
|
article
|
| 29 |
Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere
|
Raoul, Jean-Luc
|
|
|
21 |
4 |
p. 479-481
|
article
|
| 30 |
The irresistible itch
|
Kaul, Pallvi
|
|
|
21 |
4 |
p. e225
|
article
|
| 31 |
Treating childhood cancer: a necessity not a choice
|
Landman, Allison
|
|
|
21 |
4 |
p. 484-485
|
article
|
| 32 |
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|
Cremolini, Chiara
|
|
|
21 |
4 |
p. 497-507
|
article
|
| 33 |
Venetoclax for paediatric acute myeloid leukaemia: a step forward
|
Aplenc, Richard
|
|
|
21 |
4 |
p. 476-478
|
article
|
| 34 |
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
|
Karol, Seth E
|
|
|
21 |
4 |
p. 551-560
|
article
|
| 35 |
Web search queries and prostate cancer
|
Cacciamani, Giovanni E
|
|
|
21 |
4 |
p. 494-496
|
article
|
| 36 |
Worldwide benefits of improving cancer care for adolescents and young adults in LMICs
|
Osborn, Michael P
|
|
|
21 |
4 |
p. 487-489
|
article
|
Journal description